Sudeep Pharma (BOM:544619) Total Assets: ₹11,749 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544619 Sudeep Pharma Ltd BOM:544619
18 GF Score
Price ₹868.55
! 5 Warning Signs
View Full Analysis

What is Sudeep Pharma Total Assets?

Sudeep Pharma BOM:544619 -1.10% 18 Total Assets is ₹11,749 Mil as of Mar. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Sudeep Pharma's Total Assets for the quarter that ended in Mar. 2026 was ₹11,749 Mil.

During the past 12 months, Sudeep Pharma's average Total Assets Growth Rate was 59.40% per year. During the past 3 years, the average Total Assets Growth Rate was 37.60% per year.

During the past 4 years, Sudeep Pharma's highest 3-Year average Total Assets Growth Rate was 37.60%. The lowest was 37.60%. And the median was 37.60%.

Total Assets is connected with ROA %. Sudeep Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was 16.64%. Total Assets is also linked to Revenue through Asset Turnover. Sudeep Pharma's Asset Turnover for the quarter that ended in Mar. 2026 was 0.15.


Sudeep Pharma  (BOM:544619) Total Assets Explanation

Total Assets is connected with ROA %.

Sudeep Pharma's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1955.064/( (0+11748.765)/ 1 )
=1955.064/11748.765
=16.64 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sudeep Pharma's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=1788.821/( (0+11748.765)/ 1 )
=1788.821/11748.765
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sudeep Pharma Total Assets Related Terms


Sudeep Pharma Total Assets Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma Total Assets Chart

Sudeep Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Assets
4,201.13 5,138.66 7,171.71 11,748.77

Sudeep Pharma Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 0.00 7,171.71 9,222.56 0.00 11,748.77
BOM:544619
18GF Score
Sudeep Pharma Ltd BOM:544619
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sudeep Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sudeep Pharma's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (A: Mar. 2026 )+Total Liabilities (A: Mar. 2026 )
=8980.918+2767.847
=11,749

Sudeep Pharma's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=8980.918+2767.847
=11,749

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of ₹11,749 Mil mean?
Sudeep Pharma (BOM:544619) has a Total Assets of ₹11,749 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Sudeep Pharma and its competitors.
Is Sudeep Pharma's Total Assets too high?
Sudeep Pharma's current Total Assets is ₹11,749 Mil. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Total Assets compare to ZTS?
Sudeep Pharma's Total Assets of ₹11,749 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Sudeep Pharma and its competitors. Sudeep Pharma's current Total Assets is ₹11,749 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Total Assets of ₹11,749 Mil. The current Total Assets is ₹11,749 Mil. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Total Assets is ₹11,749 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sudeep Pharma Business Description

Other Exchanges SUDEEPPHRM:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score

Get the complete analysis for BOM:544619

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹868.55
Price